+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Lexiva"

Global HIV Drugs Market Analysis & Forecast to 2024-2034 - Product Thumbnail Image

Global HIV Drugs Market Analysis & Forecast to 2024-2034

  • Report
  • January 2024
  • 200 Pages
  • Global
From
US HIV Infection Drug Market, Dosage, Price, Sales Insight 2021 - 2026 - Product Thumbnail Image

US HIV Infection Drug Market, Dosage, Price, Sales Insight 2021 - 2026

  • Report
  • February 2021
  • 360 Pages
  • United States
From
  • 3 Results (Page 1 of 1)
Loading Indicator

Lexiva is a brand of antiviral drug used to treat HIV and hepatitis B and C infections. It is a protease inhibitor, meaning it works by blocking the action of a specific enzyme that the virus needs to replicate. Lexiva is typically used in combination with other antiretroviral drugs to treat HIV infection. It is also used to treat chronic hepatitis B and C infections, as well as to prevent HIV infection in people who are at high risk of contracting the virus. Lexiva is a widely used drug in the infectious diseases market, as it is effective in treating and preventing a variety of viral infections. It is also relatively well-tolerated, with few side effects. Companies in the Lexiva market include Gilead Sciences, Bristol-Myers Squibb, Merck, and AbbVie. Show Less Read more